stars 1 stars 2 stars 3

AmberGen is transforming drug development and disease research with its hyper-multiomic mass spectrometric spatial imaging technology. Our MaxOmic™ service lab performs this testing, and we also offer reagents that enable MALDI Mass Spec users to perform such imaging themselves. Our technology enables the extraction of up to six distinct spatial omics layers from each sample—all on the same instrument. These layers include drug distribution mapping for small molecule drugs (SMDs), antisense oligonucleotides (ASOs), and/or antibody-drug conjugates (ADCs), as well as spatial metabolomics/lipidomics, hyper-plex primary-antibody-targeted proteomics, secondary-antibody-targeted proteomics, targeted transcriptomics, and untargeted or targeted glycomics. Multimodal imaging—such as H&E or immunofluorescence (IF)—can also be added, all on the same tissue section. As part of our service offering, we provide AI-powered correlative multiomic analysis. Contact us at Info@AmberGen.com to learn more!

AmberGen Questions

The AmberGen annual revenue was $36 million in 2026.

John Gillespie is the President and CEO of AmberGen.

13 people are employed at AmberGen.

AmberGen is based in Billerica, Massachusetts.

The NAICS codes for AmberGen are [541, 54171, 54, 5417, 541714].

The SIC codes for AmberGen are [87, 873].

Top AmberGen Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users